Clinical trials: MS CHRONIC PROGRESSIVE
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients
Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant.
- Trial name
- NCT04550650
- Testing
- Training groupe, PNF, Spinning grp
- Where
- Hungary
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
MS CHRONIC PROGRESSIVE
Automated EDSS Score Calculation by Smartphone Application
The EDSS score is the reference tool for rating disability in patients with multiple sclerosis. It is used in both daily monitoring and clinical research studies.
- Trial name
- Easy EDSS (NCT03586635)
- Testing
- neurological exam
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Open-label Study of Liothyronine in MS
This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02506751
- Testing
- liothyronine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Background: Secondary-progressive multiple sclerosis (SP-MS) is the chronic phase of multiple sclerosis (MS). The majority of people who have relapsing-remitting MS eventually develop SP-MS.
- Trial name
- NCT01212094
- Testing
- Rituximab, normal saline
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Primary Progressive Multiple Sclerosis, Hemiparesis
Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis
Participants will receive intensive therapy through a video game in their own homes for 1 month. The game is operated by movements of the body (no controller needed) and acts like a virtual therapist.
- Trial name
- NCT03094364
- Testing
- Gaming CI Therapy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Massachusetts, Lowell
Progressive Multiple Sclerosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab.
- Trial name
- Mintaka (NCT07282574)
- Testing
- RO7268489, Ocrelizumab
- Where
- 114 sites in Australia, Brazil and 10 more
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS
Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
Multiple sclerosis (MS) is characterized pathologically by demyelination, axonal loss, and glial scar formation. Clinically, most patients have a relapsing-remitting course of MS (RRMS) that over time may become progressive…
- Trial name
- ITMTXPMS (NCT02644044)
- Testing
- Intrathecal methotrexate
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis.
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Trial name
- NCT01466114
- Testing
- estriol, Norethindrone
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Primary Progressive Multiple Sclerosis
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Background: Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that progressively weakens and destroys the pathways of the nervous system.
- Trial name
- IPPoMS (NCT00950248)
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Progressive Multiple Sclerosis
Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.
This survey will investigate the views of people with progressive MS in terms of physiotherapy services. In particular the study will examine the proportion of people with progressive MS on the MS register who use physiotherapy…
- Trial name
- NCT02559765
- Where
- United Kingdom
- Volunteers
- 1,298 people
- Sponsor
- University of Glasgow
Primary Progressive Multiple Sclerosis
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
This study is a prospective Phase 1a open-label single- center trial. It will assess the safety of intrathecal administration of DUOC-01 cells to adults with Primary Progressive Multiple Sclerosis (PPMS).
- Trial name
- DUOC for MS (NCT04943289)
- Testing
- DUOC-01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joanne Kurtzberg, MD
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Multiple sclerosis (MS) is a condition in which the immune system damages the brain and spinal cord. Treatments called disease-modifying therapies can reduce inflammation and disease activity.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- REAL-MS (NCT07899502)
- Testing
- Autologous haematopoietic stem cell transplantation (AHSCT), High-efficacy disease-modifying therapy (HE-DMT)
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Cognitive Deficits, Motor Deficits
- Trial name
- MScog-tDCS (NCT02266121)
- Testing
- tDCS
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital of Mont-Godinne
Secondary Progressive Multiple Sclerosis (SPMS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Trial name
- REMASTER (NCT07225504)
- Testing
- Remibrutinib (blinded), Remibrutinib (Open label)
- Where
- 296 sites in United States, Argentina and 34 more
- Volunteers
- 1,275 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Trial name
- NCT07067463
- Testing
- Orelabrutinib
- Where
- 76 sites in United States, Bulgaria and 14 more
- Volunteers
- 705 people
- Sponsor
- Zenas BioPharma (USA), LLC